Previous Close | 8.92 |
Open | 8.85 |
Bid | 9.30 x 1000 |
Ask | 9.55 x 800 |
Day's Range | 8.69 - 9.51 |
52 Week Range | 5.26 - 75.20 |
Volume | |
Avg. Volume | 1,429,387 |
Market Cap | 521.297M |
Beta (5Y Monthly) | 1.10 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -18.00 |
Earnings Date | Aug 08, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 14.80 |
Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced its new partnership with NOVUS International, an innovator and leader in intelligent nutrition, to develop advanced feed additives designed to meet the evolving needs of the animal agriculture industry. By utilizing Ginkgo Enzyme Services, NOVUS will work with Ginkgo to build more efficient enzymes that can be produced cost-effectively.
Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient. Ginkgo Datapoints is specialized in generating large, high-quality biological datasets with a fast turnaround time and at a competitive price per datapoint with a streamlined deal structure. Ginkgo Datapoints will launch with severa